Annual EBITDA
-$96.46 M
-$98.90 M-4045.11%
31 December 2023
Summary:
Humacyte annual earnings before interest, taxes, depreciation & amortization is currently -$96.46 million, with the most recent change of -$98.90 million (-4045.11%) on 31 December 2023. During the last 3 years, it has fallen by -$40.49 million (-72.34%). HUMA annual EBITDA is now -4045.11% below its all-time high of $2.44 million, reached on 31 December 2022.HUMA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$34.95 M
+$17.42 M+33.26%
30 September 2024
Summary:
Humacyte quarterly earnings before interest, taxes, depreciation & amortization is currently -$34.95 million, with the most recent change of +$17.42 million (+33.26%) on 30 September 2024. Over the past year, it has dropped by -$12.25 million (-53.96%). HUMA quarterly EBITDA is now -175.94% below its all-time high of $46.03 million, reached on 31 December 2021.HUMA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$137.16 M
-$12.25 M-9.81%
30 September 2024
Summary:
Humacyte TTM earnings before interest, taxes, depreciation & amortization is currently -$137.16 million, with the most recent change of -$12.25 million (-9.81%) on 30 September 2024. Over the past year, it has dropped by -$62.28 million (-83.17%). HUMA TTM EBITDA is now -383.15% below its all-time high of $48.44 million, reached on 30 September 2022.HUMA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HUMA EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4045.1% | -54.0% | -83.2% |
| 3 y3 years | -72.3% | -23.5% | -86.6% |
| 5 y5 years | - | - | - |
HUMA EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -4045.1% | at low | -175.9% | +33.3% | -383.1% | at low |
| 5 y | 5 years | -4045.1% | at low | -175.9% | +33.3% | -383.1% | at low |
| alltime | all time | -4045.1% | at low | -175.9% | +33.3% | -383.1% | at low |
Humacyte EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$34.95 M(-33.3%) | -$137.16 M(+9.8%) |
| June 2024 | - | -$52.37 M(+85.1%) | -$124.91 M(+36.4%) |
| Mar 2024 | - | -$28.29 M(+31.3%) | -$91.55 M(-5.1%) |
| Dec 2023 | -$96.46 M(-4045.1%) | -$21.55 M(-5.1%) | -$96.46 M(+28.8%) |
| Sept 2023 | - | -$22.70 M(+19.4%) | -$74.88 M(+1.5%) |
| June 2023 | - | -$19.01 M(-42.7%) | -$73.78 M(+412.7%) |
| Mar 2023 | - | -$33.20 M(<-9900.0%) | -$14.39 M(-688.6%) |
| Dec 2022 | $2.44 M | $33.00 K(-100.2%) | $2.44 M(-95.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$21.61 M(-153.5%) | $48.44 M(+16.0%) |
| June 2022 | - | $40.38 M(-346.8%) | $41.74 M(-432.6%) |
| Mar 2022 | - | -$16.36 M(-135.5%) | -$12.55 M(-9.6%) |
| Dec 2021 | -$13.89 M(-75.2%) | $46.03 M(-262.6%) | -$13.89 M(-81.1%) |
| Sept 2021 | - | -$28.30 M(+103.3%) | -$73.51 M(+17.8%) |
| June 2021 | - | -$13.92 M(-21.4%) | -$62.42 M(+28.7%) |
| Mar 2021 | - | -$17.70 M(+30.2%) | -$48.50 M(+57.5%) |
| Dec 2020 | -$55.97 M | -$13.59 M(-21.0%) | -$30.80 M(+79.0%) |
| Sept 2020 | - | -$17.21 M | -$17.21 M |
FAQ
- What is Humacyte annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Humacyte?
- What is Humacyte annual EBITDA year-on-year change?
- What is Humacyte quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Humacyte?
- What is Humacyte quarterly EBITDA year-on-year change?
- What is Humacyte TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Humacyte?
- What is Humacyte TTM EBITDA year-on-year change?
What is Humacyte annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of HUMA is -$96.46 M
What is the all time high annual EBITDA for Humacyte?
Humacyte all-time high annual earnings before interest, taxes, depreciation & amortization is $2.44 M
What is Humacyte annual EBITDA year-on-year change?
Over the past year, HUMA annual earnings before interest, taxes, depreciation & amortization has changed by -$98.90 M (-4045.11%)
What is Humacyte quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of HUMA is -$34.95 M
What is the all time high quarterly EBITDA for Humacyte?
Humacyte all-time high quarterly earnings before interest, taxes, depreciation & amortization is $46.03 M
What is Humacyte quarterly EBITDA year-on-year change?
Over the past year, HUMA quarterly earnings before interest, taxes, depreciation & amortization has changed by -$12.25 M (-53.96%)
What is Humacyte TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of HUMA is -$137.16 M
What is the all time high TTM EBITDA for Humacyte?
Humacyte all-time high TTM earnings before interest, taxes, depreciation & amortization is $48.44 M
What is Humacyte TTM EBITDA year-on-year change?
Over the past year, HUMA TTM earnings before interest, taxes, depreciation & amortization has changed by -$62.28 M (-83.17%)